Fosamax and Gingival erosion - a phase IV clinical study of FDA data

Summary:

Gingival erosion is reported as a side effect among people who take Fosamax (alendronate sodium), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Zometa, and have Pain.

The phase IV clinical study analyzes which people have Gingival erosion when taking Fosamax. It is created by eHealthMe based on reports of 104,411 people who have side effects when taking Fosamax from the FDA, and is updated regularly.

What is Fosamax?

Fosamax has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 105,452 Fosamax users. Check the latest studies of Fosamax.

What is Gingival erosion?

Gingival erosion (gum ulcer) is found to be associated with 218 drugs and 177 conditions by eHealthMe. Check the latest studies of Gingival erosion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

104,411 people reported to have side effects when taking Fosamax.
Among them, 42 people (0.04%) have Gingival erosion.

Among these 42 people:

How long have people been on Fosamax when they have Gingival erosion? *

What is the gender of people who have Gingival erosion when taking Fosamax? *

female: 100 %
male: 0.0 %

What is the age of people who have Gingival erosion when taking Fosamax? *

What are other drugs people take besides Fosamax? *

What are other side effects people have besides Gingival erosion? *

Stress And Anxiety: 32 people, 76.19%
Bone Disorder: 31 people, 73.81%
Back Pain: 29 people, 69.05%
Cellulitis (infection under the skin): 27 people, 64.29%
Pain In Extremity: 25 people, 59.52%
Osteonecrosis Of Jaw (death of bone of jaw): 24 people, 57.14%
Constipation: 23 people, 54.76%
Pain: 23 people, 54.76%
Pain In Jaw: 23 people, 54.76%
Compression Fracture (fracture due to pressure caused by injury): 21 people, 50.00%

What are the existing conditions these people have? *

Pain: 10 people, 23.81%
Metastases To Bone (cancer spreads to bone): 2 people, 4.76%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 2.38%
High Blood Cholesterol: 1 person, 2.38%
Depression: 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Fosamax and have Gingival erosion?

- Check whether Gingival erosion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fosamax:

Fosamax (105,452 reports)

Browse all side effects of Fosamax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gingival erosion:

Gingival erosion (218 drugs)

Browse all the conditions that are associated with Gingival erosion:

Gingival erosion (177 conditions)

Related publications that referenced our studies

Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Fosamax) and Fosamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.